Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

PROTAGONIST THERAPEUTICS, INC.

(PTGX)
  Report
Delayed Nasdaq  -  04:00 2022-11-29 pm EST
7.510 USD   +2.04%
11/16Protagonist Therapeutics Reports Granting of Inducement Award
PR
11/10HC Wainwright Lowers Price Target on Protagonist Therapeutics to $33 From $50, Maintains Buy Rating
MT
11/08PROTAGONIST THERAPEUTICS, INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

Protagonist Therapeutics: Q2 Earnings Snapshot

08/04/2022 | 06:09pm EST

NEWARK, Calif. (AP) _ Protagonist Therapeutics Inc. (PTGX) on Thursday reported a loss of $41 million in its second quarter.

On a per-share basis, the Newark, California-based company said it had a loss of 84 cents.

The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 99 cents per share.

The biopharmaceutical company posted revenue of $859,000 in the period.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on PTGX at https://www.zacks.com/ap/PTGX

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News

All news about PROTAGONIST THERAPEUTICS, INC.
11/16Protagonist Therapeutics Reports Granting of Inducement Award
PR
11/10HC Wainwright Lowers Price Target on Protagonist Therapeutics to $33 From $50, Maintain..
MT
11/08PROTAGONIST THERAPEUTICS, INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDIT..
AQ
11/08Protagonist Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine ..
CI
11/08Protagonist Therapeutics : Q3 Earnings Snapshot
AQ
11/02Protagonist Announces Appointment of Arturo Molina, M.D., M.S., F.A.C.P. as Chief Medic..
PR
11/02Protagonist Announces Appointment of Arturo Molina, M.D., M.S., F.A.C.P. as Chief Medic..
CI
09/20Protagonist Therapeutics Reports Granting of Inducement Award
PR
08/25JMP Securities Reinstates Protagonist Therapeutics at Market Outperform With $21 Price ..
MT
08/04Protagonist Therapeutics : Quarterly Report for Quarter Ending June 30, 2022 (Form 10-Q)
PU
More news
Analyst Recommendations on PROTAGONIST THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 31,4 M - -
Net income 2022 -125 M - -
Net cash 2022 48,8 M - -
P/E ratio 2022 -2,93x
Yield 2022 -
Capitalization 369 M 369 M -
EV / Sales 2022 10,2x
EV / Sales 2023 15,3x
Nbr of Employees 118
Free-Float 98,5%
Chart PROTAGONIST THERAPEUTICS, INC.
Duration : Period :
Protagonist Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROTAGONIST THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 7,51 $
Average target price 33,50 $
Spread / Average Target 346%
EPS Revisions
Managers and Directors
Dinesh V. Patel President, Chief Executive Officer & Director
Asif Ali Chief Financial Officer & Executive Vice President
Harold E. Selick Chairman
Mark L. Smythe Vice President-Technology
David Y. Liu Chief Research & Development Strategy Officer
Sector and Competitors
1st jan.Capi. (M$)
PROTAGONIST THERAPEUTICS, INC.-78.04%369
MODERNA, INC.-30.95%67 378
IQVIA HOLDINGS INC.-24.68%39 832
LONZA GROUP AG-34.32%39 180
ALNYLAM PHARMACEUTICALS, INC.20.76%25 738
SEAGEN INC.-24.08%22 506